title: Anti-CTLA4 antibody therapy related complications on FDG PET/CT.
abstract: Anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody therapy is a new class of drug which has demonstrated increased overall survival in patients with metastatic melanoma. Anti-CTLA-4 antibody therapy inhibits the CTLA-4 inhibitory signal, thereby enhancing the anti-tumor response of the cytotoxic T lymphocytes. This response can lead to a variety of immune-related adverse events. Many of these events are present on follow-up PET/CT examinations performed to assess response to therapy. It is important for the interpreting physician to be aware of the findings on PET/CT to avoid diagnosing adverse events as progressive disease and to alert clinicians regarding these complications.
authors: From the *Division of Nuclear Medicine, Department of Radiology, and †Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.
authors: Phillip J
authors: PJ
authors: Koo
authors: William C
authors: WC
authors: Klingensmith
authors: Karl D
authors: KD
authors: Lewis
authors: Brian M
authors: BM
authors: Bagrosky
authors: Rene
authors: R
authors: Gonzalez
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology* / Q000627:therapeutic use; D060908:CTLA-4 Antigen / Q000276:immunology*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008545:Melanoma / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy; D064847:Multimodal Imaging; D009362:Neoplasm Metastasis; D049268:Positron-Emission Tomography; D014057:Tomography, X-Ray Computed
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; D019788:Fluorodeoxyglucose F18